Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Splenic marginal zone lymphoma is a rare disease, accounting for 1% of all lymphomas. We reviewed our single center experience of 13 patients with splenic marginal zone lymphoma (SMZL). Based on the prognostic model developed by Intergruppo Italiano Linfomi, 31% (4/13) of our patients had good, 38% (5/13) had intermediate and 31% (4/13) had a poor prognosis. The presence of two out of three prognostic factors (anemia, elevated LDH, low serum albumin) assignes the patient into the high risk category. In patients with anemia and an elevated LDH due to hemolysis, the outcome seems to be especially poor. Three out of 13 (23%) cases were complicated by autoimmune hemolytic anemia. All patients with autoimmune hemolytic anaemia (AIHA) died 7-28 months after the diagnosis. The mean follow-up time of those nine patients who are still alive is longer than 5 years (36-100 months). Patients with AIHA had significantly (p∈<∈0. 001) worse survival than those without AIHA. The main finding of our study is that the presence of AIHA is an adverse prognostic factor in SMZL.

Original languageEnglish
Pages (from-to)597-603
Number of pages7
JournalPathology and Oncology Research
Volume15
Issue number4
DOIs
Publication statusPublished - Dec 1 2009

Keywords

  • Autoimmune hemolytic anemia
  • Outcome
  • Prognosis
  • Splenic marginal zone lymphoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma'. Together they form a unique fingerprint.

  • Cite this